Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Notizie Vai al feed delle notizie
Nano Dimension appoints Moshe Rozenbaum as interim CEO and Phillip Borenstein as board chairman
Nano Dimension has appointed Moshe Rozenbaum as interim CEO with immediate effect; the board also named Phillip Borenstein as chairman. Rozenbaum, previously vice president of corporate development and a board member, is to work with the board and management to ensure business continuity while strategic priorities are reviewed. Borenstein is a partner and portfolio manager at Hamilton Equity Partners and has served on the board since December 2025. » Altro su de.investing.com
Nano Dimension to combine with Infinite Epigenetics in move toward AI-powered preventive health
Nano Dimension said it is negotiating final terms of a proposed business combination with Infinite Epigenetics and will publish full details once finalized. The company defended Infinite as an operating business with a CLIA-certified methylation lab, existing commercial revenue, a network of over 7,500 healthcare providers, issued IP and a database of 120,000 samples. Nano said the term sheet values Nano at net cash plus a 20% premium, preserves its Nasdaq listing, allows holders to retain contingent value rights on legacy assets and would require a shareholder vote. The deal is framed as a strategic shift from 3D printing toward AI-driven preventive health and diagnostics. » Altro su finance.yahoo.com
Scopri gli asset
Gli azionisti di Nano Dimension ADR investono anche nei seguenti asset